Pipeline & Therapeutic
Proof of Concept

Pipeline & Therapeutic Proof
of Concept

The versatility of Gate2Brain Technology can improve drug transport for several medical indications.

Product Indication Target Discovery Lead Finding Lead Optimization Candidate Selection Pre-Clinical Phase I Phase II Phase III Product Approval Status
Non-Regulatory Regulatory
G2B-002 Pediatric
Pre-clinical non-regulatory studies

In the Case
of G2B-002

G2B-002, our flagship product, is a new therapeutic approach for pediatric tumors such as Diffuse Intrinsic Pontine Glioma (DIPG). Our peptide-shuttle carries the effective therapeutic drug to the brain to fight this devastating condition. Our approach combines oncology, rare disease and pediatrics.

DIPG is by far the most aggressive pediatric CNS tumor. DIPG is rare and there is no curative treatment for this disease. For further information on DIPG, click on the following link:
DIPG (diffuse intrinsic pontine glioma)

G2B-002 emerges as a potential approach to tackle other pediatric tumors.